FDAapproval83% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (cardiology) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Heart Failure
- Sub-indication
- Hypertension
Related signal: AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany